 "Lupin hits 32-month low; stock down 5% in two days")
Shares of Lupin dipped 2.8% to Rs 1,267, extending its Tuesday’s 2.5% fall on the BSE, after the company on Friday after market hours said US health regulator issued three observations for its Goa plant. The stock is currently trading at its lowest level since August 26, 2014.
Recently, the company’s Goa manufacturing facility underwent an inspection by the US Food and Drug Administration (USFDA). The said inspection was completed on April 7, 2017, subsequently to which, the USFDA issued Form 483 citing three observations,” Lupin said in a BSE filing.
The company is in the midst of putting together a response to address the said observations, it added.
In the past one-month, the stock declined 11.7% while the benchmark index S&P BSE Sensex remained unchanged. The company’s market capitalisation too declined by Rs 7,426 crore to Rs 57,358 crore, the BSE data showed.
Lupin’s Goa plant is one of its key plants, as it contributes around 20% to the company’s total sales [supplies to key geographies like USA, European Union (EU) and Japan, and contributed close to 40-50% to the US sales.
“Although the USFDA observations seem to be pertaining only to the routine procedures and compliance, any delay in key product approvals, if any, will add to the pressure in the US business. The guidance for key product approval is already delayed, and gSevelamer and gWelchol are now end-FY2018/early-FY2019 opportunities,” analyst at Sharekhan said in recent report.
Lupin is already facing high single digit pricing pressure in the US business on account of increasing competition in Fortamet and gGlumetza, delay in key product approvals and channel consolidation. The recent appreciation of the Indian rupee against the US dollar is likely to add to the company’s problems. Therefore, we feel that Lupin will continue to witness pressure on its US business and margins over the next few quarters, added report.
Recently, the company’s Goa manufacturing facility underwent an inspection by the US Food and Drug Administration (USFDA). The said inspection was completed on April 7, 2017, subsequently to which, the USFDA issued Form 483 citing three observations,” Lupin said in a BSE filing.
The company is in the midst of putting together a response to address the said observations, it added.
In the past one-month, the stock declined 11.7% while the benchmark index S&P BSE Sensex remained unchanged. The company’s market capitalisation too declined by Rs 7,426 crore to Rs 57,358 crore, the BSE data showed.
Lupin’s Goa plant is one of its key plants, as it contributes around 20% to the company’s total sales [supplies to key geographies like USA, European Union (EU) and Japan, and contributed close to 40-50% to the US sales.
“Although the USFDA observations seem to be pertaining only to the routine procedures and compliance, any delay in key product approvals, if any, will add to the pressure in the US business. The guidance for key product approval is already delayed, and gSevelamer and gWelchol are now end-FY2018/early-FY2019 opportunities,” analyst at Sharekhan said in recent report.
Lupin is already facing high single digit pricing pressure in the US business on account of increasing competition in Fortamet and gGlumetza, delay in key product approvals and channel consolidation. The recent appreciation of the Indian rupee against the US dollar is likely to add to the company’s problems. Therefore, we feel that Lupin will continue to witness pressure on its US business and margins over the next few quarters, added report.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%